Brief: FDA Accepts Final Protocol For Pivotal Phase 3 Alzheimer’S Disease Study, Streamlining Development Pathway
07/01/2025 13:13
Jan 7 (Reuters) - Annovis Bio Inc ANVS.N :
* FDA ACCEPTS FINAL PROTOCOL FOR PIVOTAL PHASE 3 ALZHEIMER’S
DISEASE STUDY, STREAMLINING DEVELOPMENT PATHWAY
* ANNOVIS BIO INC - INTEGRATES PHASE 3 AD STUDIES INTO
SINGLE
6/18-MONTH TRIAL
* ANNOVIS BIO INC - REVISED PROTOCOL INCLUDES 6-MONTH
SYMPTOMATIC
AND 12-MONTH DISEASE-MODIFYING ASSESSMENT
Source text: ID:nGNX5C0hvM
Further company coverage: ANVS.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Annovis Bio
See all newsAnnovis Bio Inc reports results for the quarter ended June 30 - Earnings Summary
Annovis Bio Q2 loss widens as R&D costs rise
Annovis Bio Inc expected to post a loss of 45 cents a share - Earnings Preview
Brief: Annovis Announces Pricing Of $15.0 Million Public Offering Of Common Stock And Accompanying Warrants
U.S. STOCKS ON THE MOVE-Amazon, Northrop Grumman, Brown-Forman